Zeiss is celebrating a refractive landmark of more than 10 million myopic or astigmatic eyes treated with Zeiss SMILE (small incision lenticule extraction) and Zeiss SMILE pro.  

Launched in Australia and New Zealand over a decade ago, this marks a significant milestone for the company and is proof of the growing international adoption of safe and effective lenticule extraction solutions, said Euan Thomson, president of Zeiss’ ophthalmology strategic business unit and head of digital business. "Zeiss continues to pave the way toward a future of truly personalised care through the development of some of the most advanced digital technologies and medical devices to meet the expanding needs of Europe’s leading refractive and cataract surgeons.” 

Meanwhile, Zeiss announced it is taking the lead in the industry as the first medical device manufacturer to offer treatment for hyperopia with lenticule extraction using SMILE pro in the CE markets at September’s European Society of Cataract and Refractive Surgeons conference.  

In 2011, Zeiss was the first medical device manufacturer to make lenticule extraction for laser vision correction commercially available, and Zeiss SMILE and Zeiss SMILE pro continue to be leading solutions trusted by surgeons for the technology’s proven reliability and effective treatment with Zeiss’ VisuMax and VisuMax 800, said Thomson.